Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Free Tissue Flaps | 5 | 2024 | 64 | 1.000 |
Why?
|
| Head and Neck Neoplasms | 5 | 2024 | 273 | 0.830 |
Why?
|
| Cochlear Implants | 1 | 2022 | 58 | 0.790 |
Why?
|
| Cochlear Implantation | 1 | 2022 | 72 | 0.770 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2022 | 75 | 0.770 |
Why?
|
| Speech Perception | 1 | 2022 | 90 | 0.770 |
Why?
|
| Retrospective Studies | 20 | 2024 | 6134 | 0.510 |
Why?
|
| Mandibular Reconstruction | 2 | 2023 | 15 | 0.440 |
Why?
|
| Thyroid Neoplasms | 2 | 2022 | 111 | 0.440 |
Why?
|
| Sinusitis | 2 | 2022 | 50 | 0.380 |
Why?
|
| Neck Dissection | 2 | 2021 | 31 | 0.380 |
Why?
|
| Parathyroidectomy | 2 | 2021 | 45 | 0.360 |
Why?
|
| Stapes Surgery | 2 | 2020 | 23 | 0.340 |
Why?
|
| Treatment Outcome | 8 | 2022 | 5155 | 0.330 |
Why?
|
| Tympanoplasty | 2 | 2020 | 58 | 0.320 |
Why?
|
| Meniere Disease | 1 | 2008 | 18 | 0.320 |
Why?
|
| Otolaryngology | 1 | 2008 | 56 | 0.300 |
Why?
|
| Incidental Findings | 1 | 2007 | 39 | 0.290 |
Why?
|
| Thyroidectomy | 3 | 2021 | 60 | 0.270 |
Why?
|
| Carcinoma | 1 | 2007 | 139 | 0.270 |
Why?
|
| Humans | 27 | 2024 | 50208 | 0.260 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2024 | 19 | 0.230 |
Why?
|
| Deglutition | 1 | 2024 | 42 | 0.230 |
Why?
|
| Male | 15 | 2024 | 25399 | 0.220 |
Why?
|
| Time-to-Treatment | 1 | 2024 | 66 | 0.220 |
Why?
|
| Middle Aged | 12 | 2024 | 12206 | 0.220 |
Why?
|
| Operative Time | 1 | 2023 | 73 | 0.220 |
Why?
|
| Scapula | 1 | 2023 | 19 | 0.220 |
Why?
|
| Enteral Nutrition | 1 | 2024 | 147 | 0.220 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2023 | 56 | 0.220 |
Why?
|
| Deglutition Disorders | 1 | 2024 | 77 | 0.220 |
Why?
|
| Postoperative Complications | 4 | 2024 | 996 | 0.210 |
Why?
|
| Adult | 9 | 2024 | 13324 | 0.210 |
Why?
|
| Parathyroid Hormone | 2 | 2021 | 147 | 0.210 |
Why?
|
| Tramadol | 1 | 2022 | 30 | 0.210 |
Why?
|
| Reoperation | 2 | 2021 | 454 | 0.210 |
Why?
|
| Surgical Flaps | 1 | 2023 | 120 | 0.200 |
Why?
|
| Hearing Loss, Conductive | 2 | 2019 | 54 | 0.200 |
Why?
|
| Recurrent Laryngeal Nerve Injuries | 1 | 2021 | 7 | 0.200 |
Why?
|
| Intraoperative Care | 1 | 2021 | 54 | 0.200 |
Why?
|
| Chylothorax | 1 | 2021 | 15 | 0.190 |
Why?
|
| Hypotension | 1 | 2021 | 63 | 0.190 |
Why?
|
| Aged | 9 | 2024 | 9405 | 0.190 |
Why?
|
| Vasoconstrictor Agents | 1 | 2021 | 84 | 0.190 |
Why?
|
| Robotics | 1 | 2021 | 43 | 0.190 |
Why?
|
| Paranasal Sinuses | 1 | 2020 | 18 | 0.180 |
Why?
|
| Rhinitis | 1 | 2020 | 29 | 0.180 |
Why?
|
| Morbidity | 1 | 2021 | 134 | 0.180 |
Why?
|
| Otosclerosis | 1 | 2020 | 9 | 0.180 |
Why?
|
| Intraoperative Complications | 1 | 2021 | 112 | 0.180 |
Why?
|
| Chlorides | 1 | 2020 | 50 | 0.180 |
Why?
|
| Length of Stay | 1 | 2023 | 621 | 0.180 |
Why?
|
| Ossicular Prosthesis | 1 | 2020 | 19 | 0.180 |
Why?
|
| Tympanic Membrane Perforation | 1 | 2020 | 21 | 0.180 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2020 | 35 | 0.180 |
Why?
|
| Female | 14 | 2024 | 26635 | 0.170 |
Why?
|
| Adenoma | 1 | 2021 | 110 | 0.170 |
Why?
|
| Acetaminophen | 1 | 2022 | 283 | 0.170 |
Why?
|
| Malleus | 1 | 2019 | 11 | 0.160 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 286 | 0.160 |
Why?
|
| Calcium | 1 | 2020 | 400 | 0.160 |
Why?
|
| Heart Defects, Congenital | 1 | 2023 | 585 | 0.150 |
Why?
|
| Internship and Residency | 1 | 2020 | 441 | 0.120 |
Why?
|
| Radiopharmaceuticals | 2 | 2021 | 208 | 0.110 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 1179 | 0.110 |
Why?
|
| Audiometry | 2 | 2020 | 34 | 0.090 |
Why?
|
| Tympanic Membrane | 2 | 2020 | 38 | 0.090 |
Why?
|
| Aged, 80 and over | 3 | 2022 | 3154 | 0.080 |
Why?
|
| Postoperative Period | 2 | 2020 | 168 | 0.080 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2007 | 11 | 0.070 |
Why?
|
| Whole Body Imaging | 1 | 2007 | 22 | 0.070 |
Why?
|
| Equipment Design | 1 | 2008 | 285 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2024 | 2379 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2007 | 194 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 294 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2024 | 61 | 0.060 |
Why?
|
| Incidence | 1 | 2007 | 1006 | 0.060 |
Why?
|
| Fluoroscopy | 1 | 2024 | 46 | 0.060 |
Why?
|
| Adolescent | 3 | 2020 | 6390 | 0.060 |
Why?
|
| Video Recording | 1 | 2024 | 80 | 0.060 |
Why?
|
| Fibula | 1 | 2023 | 21 | 0.060 |
Why?
|
| Critical Pathways | 1 | 2023 | 39 | 0.060 |
Why?
|
| Child | 3 | 2020 | 6851 | 0.060 |
Why?
|
| Forearm | 1 | 2023 | 32 | 0.060 |
Why?
|
| Ibuprofen | 1 | 2022 | 21 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2023 | 125 | 0.050 |
Why?
|
| Thyroid Gland | 1 | 2022 | 73 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 31 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2023 | 222 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2002 | 51 | 0.050 |
Why?
|
| Pain, Postoperative | 1 | 2022 | 158 | 0.050 |
Why?
|
| Recurrent Laryngeal Nerve | 1 | 2021 | 13 | 0.050 |
Why?
|
| Laryngeal Nerves | 1 | 2021 | 16 | 0.050 |
Why?
|
| Glossectomy | 1 | 2021 | 6 | 0.050 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2021 | 18 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2020 | 3883 | 0.050 |
Why?
|
| Head | 1 | 2021 | 73 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 213 | 0.050 |
Why?
|
| Acute Disease | 1 | 2022 | 368 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2021 | 118 | 0.050 |
Why?
|
| Tongue | 1 | 2021 | 39 | 0.050 |
Why?
|
| Neck | 1 | 2021 | 100 | 0.050 |
Why?
|
| Risk | 1 | 2022 | 324 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 377 | 0.050 |
Why?
|
| Arteries | 1 | 2021 | 92 | 0.050 |
Why?
|
| Data Collection | 1 | 2022 | 277 | 0.050 |
Why?
|
| Stapes | 1 | 2020 | 12 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 246 | 0.050 |
Why?
|
| Cartilage | 1 | 2020 | 48 | 0.040 |
Why?
|
| Self-Assessment | 1 | 2020 | 46 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 697 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2002 | 239 | 0.040 |
Why?
|
| Young Adult | 2 | 2020 | 3981 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2021 | 546 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 388 | 0.040 |
Why?
|
| Endoscopy | 1 | 2020 | 124 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 1185 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2022 | 435 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2022 | 1126 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2023 | 2190 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2020 | 571 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2002 | 394 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2023 | 1161 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2022 | 1262 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 557 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2020 | 392 | 0.040 |
Why?
|
| Apoptosis | 1 | 2002 | 1112 | 0.030 |
Why?
|
| Quality of Life | 1 | 2020 | 839 | 0.030 |
Why?
|
| Prognosis | 1 | 2019 | 1954 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2002 | 1186 | 0.030 |
Why?
|
| Cytochrome c Group | 1 | 2002 | 5 | 0.010 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2002 | 14 | 0.010 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2002 | 20 | 0.010 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2002 | 30 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2002 | 86 | 0.010 |
Why?
|
| Caspases | 1 | 2002 | 104 | 0.010 |
Why?
|
| Ligands | 1 | 2002 | 205 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2002 | 125 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 468 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2002 | 601 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2002 | 306 | 0.010 |
Why?
|
| Cell Survival | 1 | 2002 | 602 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2002 | 314 | 0.010 |
Why?
|